期刊
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
卷 57, 期 1, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ijantimicag.2020.106216
关键词
Artemisinin; Piperaquine; COVID-19; Antimalarial; SARS-CoV-2
资金
- Natural Science Foundation of China [81873218]
- China Postdoctoral Science Foundation [2019M662875]
- Scientific Research Projects for Novel Coronavirus-infected Pneumonia Prevention and Control of the Education Department of Guangdong province, China [2020KZDZX1055]
- Emergent Scientific and Technological Special Project for Novel Coronavirus-infected Pneumonia Prevention and Control of Guangdong Province, China [2020A111128013]
- National Major Science and Technology Special Project [2018ZX09303008]
- Bureau of Traditional Chinese Medicine Project of Guangdong Province, China [[2019]43]
There are no effective therapies for patients with coronavirus disease-2019 (COVID-19). In patients with mild-to-moderate COVID-19, the time to reach undetectable SARS-CoV-2 was significantly shorter in the artemisinin-piperaquine group than that in the control group. However, physicians should consider QT interval changes before using artemisinin-piperaquine.
Background: There are no effective therapies for patients with coronavirus disease-2019 (COVID-19). Methods: Forty-one patients with confirmed COVID-19 were enrolled in the study and divided into two groups: artemisinin-piperaquine (AP) (n = 23) and control (n = 18). The primary outcome were the time taken to reach undetectable levels of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) and the percentage of participants with undetectable SARS-CoV-2 on days 7, 10, 14, and 28. The computed tomography (CT) imaging changes within 10 days, corrected QT interval changes, adverse events, and abnormal laboratory parameters were the secondary outcomes. Results: The mean time to reach undetectable viral RNA (mean +/- standard deviation) was 10.6 +/- 1.1 days (95% confidence interval [CI] 8.4-12.8) for the AP group and 19.3 +/- 2.1 days (95% CI 15.1-23.5) for the control group. The percentages of patients with undetectable viral RNA on days 7, 10, 14, 21, and 28 were 26.1%, 43.5%, 78.3%, 100%, and 100%, respectively, in the AP group and 5.6%, 16.7%, 44.4%, 55.6%, and 72.2%, respectively, in the control group. The CT imaging within 10 days post-treatment showed no significant between-group differences (P > 0.05). Both groups had mild adverse events. Conclusions: In patients with mild-to-moderate COVID-19, the time to reach undetectable SARS-CoV-2 was significantly shorter in the AP group than that in the control group. However, physicians should consider QT interval changes before using AP. (C) 2020 The Author(s). Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据